Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EPICA-1: 1,3-β-D-glucan vs Blood Culture in Suspected Invasive Candidiasis
NCT03906916Phase 4Terminated
- Sponsor
- Fondazione FADOI
- Start
- Jul 2018
- Primary completion
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of micafungin in invasive candidiasis, sponsored by Fondazione FADOI. Primary endpoint: Equivalence between 1,3-β-D-glucan and blood culture at 14 days. Started Jul 2018; status: terminated.
02
Drugs
micafungin
03
Conditions
invasive candidiasis
Beyond the preview
Go deeper on NCT03906916.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03906916.